How long will chronic myeloid leukemia (CML) patients treated with imatinib mesylate live?
The stepwise approval of imatinib mesylate for the treatment of Philadelphia (Ph) chromosome-positive CML since 2001 occured mainly due to the remarkably high proportion of patients who achieved a partial or complete cytogenetic response. Whereas patients treated with interferon alfa (IFN) showed a major cytogenetic remission (MCR) rate between 7 and 37%, 1 the randomized IRIS trial 2 demonstrated a remission rate of 85% for patients treated with imatinib within 18 months. As MCR is a surrogate measure only, patients, physicians and sickness funds alike want to know how long patients treated with imatinib will live compared to those treated with IFN, the pharmacotherapy with longest and best follow-up data.
There is clear evidence that MCR is a valid surrogate measure for the survival of low-and intermediate-risk patients treated with IFN. 3, 4 Assuming this for imatinib-treated patients too, it is possible to estimate their expected survival probabilities by combining the survival increment as observed in IFN-treated patients with MCR and the substantially higher rate of MCR achieved with imatinib.
From the Collaborative Prognostic Factors Project, 5 our database comprised 658 IFN-treated patients with complete data on cytogenetic response and an observation of survival 421 months. A minimum of 20 metaphases had to be evaluated. Details on patient characteristics and the New CML score have been reported elsewhere. 5 With regard to imatinib information on MCR as published by the IRIS trial was used. 2 The percentage of MCR recorded up to 21 months was 26% with IFN. Survival probabilities in patients with and without MCR are shown in Table 1 . The survival probabilities observed for a specific combination from New CML score (low, intermediate, high) and MCR (yes, no) in IFN-treated patients were assumed to be the same for patients treated with imatinib. The proportion of MCR among imatinib-treated patients was 85% at 18 months. 2 The same percentage was assumed at 21 months.
According to the 85% MCR rate, for estimating the survival probabilities of imatinib-treated patients, three samples were constituted by randomly drawing 85% of their patients of the IFN-treated patients with MCR and 15% out of the IFN-treated patients lacking MCR. The overall risk group distribution of the first simulated patient sample was chosen to be the same as for the 658 IFN patients: 41% low risk, 48% intermediate risk and 11% high risk. Regarding the second and third sample, simulations were performed only within the low-risk and intermediate-risk group, respectively.
For the total patient sample consisting of low-, intermediateand high-risk patients, median survival time with imatinib was not yet reached, whereas 75 months were observed for IFN ( Figure 1 ). The estimated 10-year survival probability for imatinib was 51% compared to 26% with IFN.
Stratified for risk group, the higher percentage of MCR with imatinib resulted in an estimated 10-year survival probability of 66% for imatinib-treated low-risk patients compared to 37% for interferon (median survival time: 95 months) ( Figure 2) ; the corresponding figures for intermediate-risk patients were 53 vs 22% (median survival time: 72 months) (Figure 3) . A separate analysis for high-risk patients was not performed, since no relevant increment in survival time was seen for these patients when treated with IFN.
In contrast to IFN-based treatments, the MCR rate of patients treated with imatinib is much higher. However, due to the relatively short observation period, long-term survival with imatinib treatment is not yet known. However, physicians and patients need to know how the higher MCR rate achieved with imatinib will most likely translate into survival time. We combined the survival increments seen in IFN-treated CML patients stratified for prognostic groups and MCR (yes, no), with the higher MCR rates seen in patients treated with imatinib in the randomized IRIS trial. 2 This is the first data-based estimation of the expectable survival benefits for chronic phase CML patients treated with imatinib.
The expected absolute increment of the 10-year survival rate by 25-31% is a rather conservative estimate, since we assumed for imatinib at the landmark 21 months identical survival probabilities around 95% as were observed with IFN. Besides, we used the MCR rate achieved with imatinib until month 18 (as the MCR rate at month 21 was not available) and assumed for the total sample that in imatinib-treated high-risk patients as in those treated with IFN, MCR does not improve survival. MCR rather than complete cytogenetic remission (CCR) rate was applied, since the frequency of CCR (until 21 months: n ¼ 61; 9.3% of 658) in the IFN sample was too low to be used for such computations. However, for imatinib, a CCR rate of 73.8% was reported and, in general, an even greater increment in survival time in patients with CCR is expected.
It is still not known whether MCR under imatinib generates the same survival increment as seen with IFN, but quantitative PCR analyses indicated that the Ph þ clone is even more Number of patients who died after 21 months.
Figure 1
Total patient sample. Prognosticated survival probabilities for imatinib treatment vs survival estimated under IFN treatment.
Figure 2
Low-risk patients according to the New CML score. Prognosticated survival probabilities for imatinib treatment vs survival estimated under IFN treatment.
Editorial

J Hasford et al
reduced with imatinib than with IFN, 6, 7 and first reports suggested that cytogenetic response is a predictor for survival under imatinib, too. 8 Emerging evidence that imatinib rarely leads to molecular complete remission and that many patients are still at risk of relapse and other clonal disorders is of concern 9,10 and emphasizes the need for long-term data of effectiveness.
As imatinib was introduced into the treatment of CML since 2001 only, it will take some years before valid survival time data will be available. For the time being, we consider the expected outcome data presented here as the methodologically best and fair estimates.
